Page last updated: 2024-11-04

thymine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1135
CHEMBL ID993
CHEBI ID17821
SCHEMBL ID5235
SCHEMBL ID15496760
SCHEMBL ID16356870
MeSH IDM0021455

Synonyms (110)

Synonym
AKOS002337369
2,4(1h,3h)-pyrimidinedione, 5-methyl-, labeled with tritium
(3h)methylthymidine
thymine-t
methyl-3h thymidine
2792-47-4
THY ,
5-methylpyrimidine-2,4(1h,3h)-dione
CHEBI:17821 ,
5-methyl uracil
nsc14705 ,
thymin (purine base)
2,4-dihydroxy-5-methylpyrimidine
thymine anhydrate
thymin
2,3h)-pyrimidinedione, 5-methyl-
wln: t6n cnj bq dq e1
nsc-14705
3059-73-2
5-methyl-1h-pyrimidine-2,4-dione
inchi=1/c5h6n2o2/c1-3-2-6-5(9)7-4(3)8/h2h,1h3,(h2,6,7,8,9
2,4(1h,3h)-pyrimidinedione, 5-methyl-
5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
2,4(1h,3h)-pyrimidinedione, 5-methyl- (9ci)
ai3-25479
5-methyl-2,4-dihydroxypyrimidine
ccris 5584
thymine (8ci)
5-methylpyrimidine-2,4-dione
5-methyl-2,4(1h,3h)-pyrimidinedione
5-methyluracil
65-71-4
thymine ,
C00178
thymine, suitable for cell culture, bioreagent
thymine, >=99%
DB03462
nsc-168663
nsc 14705
einecs 200-616-1
thymine (van)
T-3845
5 methyluracil
AC-7756
036B9F1D-9B61-4CED-967C-BF1DA180E5C2
bdbm50134397
CHEMBL993 ,
T0234
AKOS000120923
A835203
qr26ylt7lt ,
unii-qr26ylt7lt
5-methy uracil(thymine)
S9382
5-methylpyrimidine-2,4(1h,3h)-dione (thymine)
STL280241
FT-0675207
thymine-methyl-d3-6-d
FT-0602550
EPITOPE ID:167476
gtpl4581
STL477641
5-methylpyrimidine-2,4-diol
thymine [who-dd]
stavuine impurity a [who-ip]
thymine [usp impurity]
zidovudine impurity c [ep impurity]
thymine [inci]
thymine [mi]
zidovudine impurity c [who-ip]
AM81332
SCHEMBL5235
5-methyl-uracil
4-hydroxy-5-methylpyrimidin-2(1h)-one
SCHEMBL15496760
dtxsid4052342 ,
tox21_303929
dtxcid4030914
NCGC00357169-01
cas-65-71-4
5-methyl-2,4-dioxypyrimidine
mfcd00006026
zidovudine impurity c
SCHEMBL16356870
F0001-1753
SR-01000945223-1
sr-01000945223
thymine, vetec(tm) reagent grade, 99%
2.6-dioxy-5-methyl-pyrimidin
153445-43-3
4(3h)-pyrimidinone, 2-hydroxy-5-methyl- (9ci)
CS-W011166
123430-67-1
4(1h)-pyrimidinone, 2-hydroxy-5-methyl- (9ci)
HY-W010450
SY014896
FT-0771534
BCP22973
thymine,(s)
zidovudine ep impurity c
Q171973
cid 5274265
EN300-21969
CCG-266101
thymine-13c1
SB57778
stavuine impurity a
zidovudine impurity c (ep impurity)
thymine (usp impurity)
Z147641104

Research Excerpts

Overview

Thymine dimers are a major mutagenic photoproduct induced by UV radiation. Thymine glycol (Tg) is a common product of oxidation and ionizing radiation, including that used for cancer treatment.

ExcerptReferenceRelevance
"Thymine dimers are a major mutagenic photoproduct induced by UV radiation. "( The interplay of supercoiling and thymine dimers in DNA.
Doye, JPK; Lim, W; Louis, AA; Randisi, F, 2022
)
2.44
"Thymine glycol (Tg) is a common product of oxidation and ionizing radiation, including that used for cancer treatment. "( A structural rationale for stalling of a replicative DNA polymerase at the most common oxidative thymine lesion, thymine glycol.
Aller, P; Doublié, S; Hogg, M; Rould, MA; Wallace, SS, 2007
)
2
"Thymine glycol is a DNA damage product of ionizing radiation and other oxidative mutagens. "( Thymine glycol and thymidine glycol in human and rat urine: a possible assay for oxidative DNA damage.
Ames, BN; Cathcart, R; Saul, RL; Schwiers, E, 1984
)
3.15
"Thymineless death is an important cytotoxic response to several classes of antimetabolite agents used in the treatment of patients with carcinomas and hematopoeitic malignancies. "( Cellular responses to antimetabolite anticancer agents: cytostasis versus cytotoxicity.
Houghton, JA; Houghton, PJ, 1996
)
1.74
"Thymine glycol is a major type of base damage, which is formed in DNA by reactive oxygen species. "( Synthesis and thermodynamic studies of oligonucleotides containing the two isomers of thymine glycol.
Iwai, S, 2001
)
1.98
"Thymine glycol (Tg) is a product of DNA damage by oxygen radicals generated by oxidative mutagens and carcinogens and ionizing radiation. "( 32P-postlabeling detection of thymine glycols: evaluation of adduct recoveries after enhancement with affinity chromatography, nuclease P1, nuclease S1, and polynucleotide kinase.
Blackburn, GR; Bleicher, WT; Reddy, MV, 1991
)
2.01

Effects

6-Azathymine has very little effect on the change of penicillinase activity. The thymine base has been tethered to a distal triphenylmethoxy moiety through a polymethylene chain (n = 3-8)

ExcerptReferenceRelevance
"6-Azathymine has very little effect on the change of penicillinase activity."( METABOLIC CONTROL OF PENICILLINASE BIOSYNTHESIS IN BACILLUS CEREUS.
DAY, RA; SHAH, R; YIP, LC, 1964
)
0.7
"The thymine base has been tethered to a distal triphenylmethoxy moiety through a polymethylene chain (n = 3-8) or through a (2-ethoxy)ethyl spacer."( N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors.
Balzarini, J; Camarasa, MJ; Familiar, O; Gago, F; Hernandez, AI; Karlsson, A; Negri, A; Pérez-Pérez, MJ; Rodríguez-Barrios, F, 2006
)
1.17
"Thymineless death has been studied in four different Thy(-) strains of Escherichia coli by using various assay methods including conventional plating techniques as well as one performed entirely in liquid medium. "( Thymineless death in Escherichia coli in various assay systems: viability determined in liquid medium.
Couch, JL; Nakayama, H, 1973
)
3.14
"Once thymineless death has commenced, the rate in polA(-) cells is only slightly faster than in polA(+) cells."( Thymineless death in polA+ and polA- strains of Escherichia coli.
Berg, CM; O'Neill, JM, 1973
)
2.15

Treatment

ExcerptReferenceRelevance
"The treatment of thymine with dimethylarsinous iodide (DMI), a model compound of dimethylarsinous acid, induced the formation of cis-thymine glycol."( Oxidative DNA damage following exposure to dimethylarsinous iodide: the formation of cis-thymine glycol.
Hasegawa, A; Hoshino, M; Mizoi, M; Okada, S; Tachikawa, M; Yamanaka, K, 2003
)
0.87

Toxicity

ExcerptReferenceRelevance
" Expression of the ogt ATase provided greater protection against the toxic effects of the alkylating agents then the ada ATase particularly with N-ethyl-N-nitrosourea (ENU) and N-butyl-N-nitrosourea (BNU) to which the ada ATase expressing cells were as sensitive as parent vector transfected cells."( Expression in mammalian cells of the Escherichia coli O6 alkylguanine-DNA-alkyltransferase gene ogt reduces the toxicity of alkylnitrosoureas.
Harris, LC; Margison, GP, 1993
)
0.29
" Caspase-3 activation occurs with some ONs and it is most likely secondary to necrosis rather than apoptosis, since cells treated with toxic ONs did not show chromatin condensation, but did exhibit high-extracellular lactate dehydrogenase activity."( Sequence-dependent cytotoxicity of second-generation oligonucleotides.
Barone, S; Bennett, CF; Drygin, D, 2004
)
0.32
"The applicability of Density Functional Theory (DFT) based descriptors for the development of quantitative structure-toxicity relationships (QSTR) is assessed for two different series of toxic aromatic compounds, viz."( Toxicity prediction of PHDDs and phenols in the light of nucleic acid bases and DNA base pair interaction.
Mondal Roy, S; Roy, DR; Sahoo, SK, 2015
)
0.42
" The most common grade 3 or 4 adverse events were neutropenia (41."( Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Bando, H; Doi, T; Fukuoka, S; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Ohtsu, A; Okamoto, W; Shitara, K; Yoshino, T, 2016
)
0.43
" Major adverse events were neutropenia, leukopenia, anemia, and nausea."( Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016
)
0.43
" The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%)."( Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
Akashi, K; Arita, S; Ariyama, H; Baba, E; Esaki, T; Hirano, G; Kusaba, H; Makiyama, A; Matsushita, Y; Mitsugi, K; Shibata, Y; Shimokawa, HK; Shirakawa, T; Tamura, S, 2016
)
0.43
" Adverse events to TAS-102 monotherapy were observed in 22 out of 23 cases (95."( Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016
)
0.43
" This postmarketing surveillance study investigated expected and unexpected adverse drug reactions (ADRs) of TAS-102 in clinical practice in the first 6 months after market launch."( TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study.
Fujita, N; Furuta, T; Hara, N; Katori, J; Muro, K; Uetake, H; Yoshino, T, 2016
)
0.43
" Drug-related adverse events (AEs) and grade ≥3 AEs were 23 (100%) and 10 (43."( Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H, 2016
)
0.43
" Integrated data from a larger group of mCRC patients receiving trifluridine/tipiracil at the recommended starting dose (group 1) and nonintegrated data on serious adverse events (SAEs) representing all clinical experience with trifluridine/tipiracil as of the data cutoff date (group 3) are also summarized."( Integrated safety summary for trifluridine/tipiracil (TAS-102).
Bebeau, P; Bendell, JC; Buscaglia, M; Falcone, A; Kopetz, S; Mayer, RJ; Ohtsu, A; Van Cutsem, E; Yoshino, T, 2018
)
0.48
" This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive factors; efficacy and usefulness in detection of laboratory markers, electrocardiographic changes and cardiac imaging; and specific treatment, including a novel agent, uridine triacetate."( Fluoropyrimidine-induced cardiotoxicity.
Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D, 2018
)
0.48
"Recent toxicological assessments of graphene, graphene oxides, and some other two-dimensional (2D) materials have shown them to be substantially toxic at the nanoscale, where they inhibit and eventually disrupt biological processes."( Gauging the Nanotoxicity of h2D-C
Bhattacharyya, K; Datta, A; Mukhopadhyay, TK, 2018
)
0.48
" The Grade 3 or worst adverse event that was experienced was neutropenia."( [Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report].
Arakawa, S; Asano, Y; Horiguchi, A; Imaeda, Y; Isetani, M; Ishihara, S; Ito, M; Ito, R; Kamio, K; Kawabe, N; Kawai, T; Nagata, H; Shimizu, K; Tomishige, H; Yasuoka, H, 2018
)
0.48
" Associations of serious fluoropyrimidine adverse effects have focused on inherited deficiency of the catabolic enzyme, dihydropyrimidine dehydrogenase."( Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients.
Charles, BG; Cowley, D; Duley, JA; George, R; Harris, M; Helsby, N; Ni, M; Norris, RL; Shannon, C; Sheffield, L; van Kuilenburg, ABP, 2018
)
0.76
" Overall, no adverse events other than neutropenia were noted."( Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer.
Narihiro, S; Ohtsu, M; Okamoto, T; Ryu, S; Shimoyama, Y; Suwa, K; Ushigome, T; Yanaga, K,
)
0.13
"5% of patients (n = 101), 253 adverse events (AE) were documented, most of them drug-related (n = 135)."( Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
Fuchs, M; Karthaus, M; Kasper, S; Kisro, J; Müller, C; Rafiyan, MR; Schulz-Abelius, A; Stein, A, 2018
)
0.48
"0%) had at least 1 adverse event leading to study discontinuation."( Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
Bebeau, P; Becerra, C; Rosen, L; Rudek, MA; Saif, MW; Shepard, DR; Sun, W; Winkler, R; Yamashita, F, 2019
)
0.51
"1% both) were the most frequent adverse events."( Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F, 2020
)
0.56
" The most common grade ≥ 3 adverse events in trifluridine-tipiracil groups in Phase II and III trials were neutropenia, anemia, and leukopenia."( The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan, BM; Hochster, HS; Lenz, HJ, 2019
)
0.51
" Among FTD/TPI-treated patients, grade 3 or higher adverse events of any cause occurred in 122 of 145 patients (84."( Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.
Alsina, M; Arkenau, HT; Beretta, GD; Catenacci, D; Doi, T; Fujitani, K; George, B; Ghidini, M; Ilson, DH; Makris, L; Mansoor, W; McGuigan, S; Prokharau, A; Shitara, K; Tabernero, J; Thuss-Patience, P; Van Cutsem, E; Zhavrid, E, 2020
)
0.56
" Cases (n = 9) and noncases (n = 23) of severe (grade ≥ 3) gastrointestinal toxicity were defined based on Common Terminology Criteria for Adverse Events."( A case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity.
Barlow, P; Bonnet, C; Brenman, E; Burns, KE; Duley, J; Findlay, M; Helsby, NA; Jeong, SH; Porter, D; Sharples, K, 2020
)
0.81
" Fruquintinib exhibited better PFS, good tolerability and reduced gastrointestinal adverse effects in wild-type KRAS subgroup, making it a promising agent to treat patients with wild-type KRAS mCRC beyond the second line."( Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials.
Cao, M; Zhang, J; Zhou, M, 2020
)
0.56
" Adverse events (AEs) were experienced by 96."( Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
Atlan, D; Bachet, JB; Becquart, M; Cicin, I; Cremolini, C; Falcone, A; Mounedji, N; Ozet, A; Phelip, JM; Portales, F; Price, T; Taieb, J; Van Cutsem, E; Vidot, L; Wyrwicz, L, 2020
)
0.56
" Overall survival (OS) and adverse events were compared between the groups."( Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study.
Kawakami, K; Nakashima, M; Takeuchi, M, 2020
)
0.56
" The incidences of most adverse events were the lowest in the TFTD group."( Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study.
Kawakami, K; Nakashima, M; Takeuchi, M, 2020
)
0.56
" Common treatment-related adverse events of grade 3 or worse were neutrophil count decreased (27 [82%] in cohort A and 23 [74%] in cohort B), white blood cell count decreased (eight [24%] and seven [23%]), and platelet count decreased (eight [24%] and four [13%])."( Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
Amagai, K; Ando, T; Fujita, J; Fujitani, K; Hosaka, H; Kawazoe, A; Koeda, K; Nishikawa, K; Ogata, K; Shitara, K; Watanabe, K; Yamamoto, Y, 2021
)
0.62
" Although the incidence of hematological toxicity in the elderly patient group was higher than that in the younger patient group, there were no significant differences in the rate of treatment discontinuation due to adverse events between the two groups."( The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
En, W; Fukuoka, T; Hirakawa, K; Iseki, Y; Kashiwagi, S; Ohira, M; Okazaki, Y; Shibutani, M, 2021
)
0.62
" Among FTD/TPI-treated patients, frequencies of any-cause grade ≥ 3 adverse events (AEs) were similar across age subgroups (80% each), although grade ≥ 3 neutropenia was more frequent in older patients [40% (≥ 65 and ≥ 75 years); 29% (< 65 years)]; AE-related discontinuation rates did not increase with age [14% (< 65 years), 12% (≥ 65 years), and 12% (≥ 75 years)]."( Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Alsina, M; Benhadji, KA; Cicin, I; Doi, T; Hosaka, H; Ilson, DH; Longo, F; Makris, L; Özgüroğlu, M; Ozyilkan, O; Park, D; Pericay, C; Santoro, A; Shitara, K; Thuss-Patience, P; Zaanan, A, 2022
)
0.72
" The most frequent treatment-emergent adverse events were neutropenia (27."( Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.
Ettrich, TJ; Heinemann, V; Hess, J; Karthaus, M; Klein, A; Kretzschmar, A; Pelz, H; Reisländer, T; Riera-Knorrenschild, J; Vehling-Kaiser, U; Weiss, L; Welslau, M, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" Only the pharmacokinetic aspects of these studies are reported in this paper."( Pharmacokinetic studies during phase I trials of high-dose thymidine infusions.
Bolten, BJ; Chiuten, D; Wiernik, PH; Zaharko, DS, 1979
)
0.26
" The pharmacokinetic profile varied considerably from one compound to another."( Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives.
Baba, M; De Clercq, E; Iida, S; Nakashima, H; Nitta, I; Sekiya, K; Takashima, H; Tanaka, H; Ubasawa, M; Umezu, K, 1990
)
0.28
" Evidence was obtained to show that the metabolic elimination of these pyrimidines is saturable, resulting in nonlinear pharmacokinetic behavior."( Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs.
Covey, JM; Straw, JA, 1983
)
0.53
" In this study, a pharmacokinetic model was developed, in an attempt to evaluate the bioavailability of FTD in these animals after the co-administration of TPI."( Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor.
Harashima, H; Kamiya, H; Kuwata, K; Nagayama, S; Tsuchiya, H; Yamashita, K, 2004
)
0.32
"The purpose of the current study was to determine the maximum tolerated dose, dose-limiting toxicities, pharmacokinetic profile, and recommended Phase II dose of oral administration of TAS-102, a novel nucleoside formed by the combination of alpha,alpha,alpha-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI: 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione)."( Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Abbruzzese, JL; Bogaard, K; Fukushima, M; Hoff, PM; Hong, DS; Kuwata, K; Lassere, Y; Mita, A, 2006
)
0.33
"The Hollow Fibre Assay (HFA) is usually applied as an early in vivo model for anti-cancer drug screening, but is potentially an excellent model for short-term in vivo pharmacodynamic studies."( The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Peters, GJ; Prins, HJ; Temmink, OH; van Gelderop, E, 2007
)
0.34
" The pharmacokinetic profile of GBP was examined."( The effect of MDR1 G2677T/A polymorphism on pharmacokinetics of gabapentin in healthy Korean subjects.
Cho, HY; Kang, HA; Lee, YB, 2007
)
0.34
" The pharmacokinetic profiles of D-DOT in serum and urine were adequately described by a two-compartment open pharmacokinetic model."( Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
Asif, G; Chu, CK; Delinsky, D; Hurwitz, SJ; McClure, HM; Narayanasamy, J; Obikhod, A; Schinazi, RF, 2007
)
0.56
" Also a complete 12-hour pharmacokinetic profile was recorded for 15 transplant patients who had the polymorphism and for 15 controls who were randomly chosen since they received the same type and dosage of mycophenolate, same posttransplant time and similar renal function."( The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients.
Arroyo, M; Barrientos, A; Calvo, N; De la Orden, V; Maestro, ML; Ortega, D; Pérez-Flores, I; Sánchez-Fructuoso, AI; Veganzone, S; Viudarreta, M,
)
0.13
" A pilot pharmacokinetic study analysed plasmas and urines from 2 healthy male subjects who each received an oral 250 mg THY dose."( Simultaneous determination of thymine and its sequential catabolites dihydrothymine and β-ureidoisobutyrate in human plasma and urine using liquid chromatography-tandem mass spectrometry with pharmacokinetic application.
Charles, B; Duley, J; George, R; McGeary, R; Ni, M; Norris, R; Shannon, C, 2013
)
0.68
" The pharmacokinetic data of healthy volunteers were analysed assuming a non-compartmental model."( Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males.
Cameron, A; Charles, BG; Duley, JA; George, R; Harris, M; Helsby, N; Mead, S; Ni, M; Norris, RL; Shannon, C; Sheffield, L; van Kuilenburg, AB, 2016
)
0.66
" Patients were given single doses of TAS-102 (35 mg/m(2) ) in the pharmacokinetic phase and received twice-daily doses of TAS-102 in 28-day cycles in the repeated administration phase for evaluating efficacy and safety."( Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"Treatment with Bmab in combination with TAS-102 is significantly associated with improved clinical outcomes in patients with mCRC refractory to standard therapies."( Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Fujii, H; Hirose, C; Iihara, H; Ishihara, T; Kitahora, M; Matsuhashi, N; Suzuki, A; Takahashi, T; Watanabe, D; Yamada, Y; Yoshida, K, 2020
)
0.56
" Treatment with Bmab in combination with TAS-102 is significantly associated with improved clinical outcomes in patients with mCRC."( Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Fujii, H; Hirose, C; Iihara, H; Ishihara, T; Kitahora, M; Matsuhashi, N; Suzuki, A; Takahashi, T; Watanabe, D; Yamada, Y; Yoshida, K, 2020
)
0.56
"TAS-102 is a preconstituted drug combination comprising an oral fluoropyrimidine (trifluridine, TFT) and a potent inhibitor of thymidine phosphorylase (tipiracil hydrochloride, TPI)."( TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination.
Aprile, G; Cianchi, F; Fancelli, S; Gatta Michelet, MR; Lavacchi, D; Mini, E; Nobili, S; Roviello, F; Roviello, G, 2020
)
0.56
" The favorable safety profile of trifluridine/tipiracil renders it a suitable option to be combined with other local therapies for metastatic lesions."( Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report.
Lin, BR; Lin, YL; Liu, KL, 2020
)
0.56
"The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies."( Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Giuliani, J, 2022
)
0.72
"Trifluridine/tipiracil could be consider a cost-effective treatment also in first-line for mCRC patients who were not candidates for combination with cytotoxic chemotherapies."( Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Giuliani, J, 2022
)
0.72
"We conducted a phase I study to evaluate the maximum tolerated dose (MTD), safety, and efficacy of trametinib in combination with TAS-102 in patients with chemotherapy-refractory KRAS-mutant, wild-type PIK3CA/PTEN metastatic colorectal cancer (mCRC)."( A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer.
Chuang, J; Fakih, M; Gong, J; Li, SM; Wang, C, 2022
)
0.72
"Trametinib in combination with TAS-102 demonstrated a manageable safety profile."( A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer.
Chuang, J; Fakih, M; Gong, J; Li, SM; Wang, C, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" Mean oral bioavailability of D4T was high at approximately 70%."( In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine.
Cretton, EM; Hitchcock, MJ; Kaul, S; Kidd, LB; McClure, HM; Sommadossi, JP; Zhou, Z, 1993
)
0.29
" In this study, a pharmacokinetic model was developed, in an attempt to evaluate the bioavailability of FTD in these animals after the co-administration of TPI."( Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor.
Harashima, H; Kamiya, H; Kuwata, K; Nagayama, S; Tsuchiya, H; Yamashita, K, 2004
)
0.32
" Uracils bearing a side chain derived from phenylglycinol at the 3-position were shown to be orally bioavailable in monkeys."( 3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in
Acevedo, O; Bonneville, AK; Bozigian, H; Chen, C; Chen, T; Gao, Y; Gross, TD; Guo, Z; Ling, N; Liu, XJ; Reinhart, GJ; Rowbottom, MW; Saunders, J; Struthers, RS; Tucci, FC; Xie, Q; Zhu, YF, 2005
)
0.33
" The thymidine analog trifluorothymidine (TFT) has been shown to bypass resistance pathways for 5FU derivatives (S-1, UFT, Xeloda) in model systems, while concurrent application with a thymidine phosphorylase inhibitor (TPI) increases the bioavailability of TFT, thereby potentiating the in vivo efficacy of TFT."( Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
de Bruin, M; Emura, T; Fukushima, M; Peters, GJ; Temmink, OH, 2007
)
0.34
" The bioavailability of CsA and FK506 seems to be associated with the cytocrhome P450 IIIA (CYP3A) gene."( Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
Breitenfeld, L; Martinho, A; Mendes, J; Mota, A; Pais, L; Simoes, O, 2009
)
0.35
" TAS-102 is an oral combination therapy consisting of trifluridine (FTD), a thymidine-based nucleoside analog, plus tipiracil hydrochloride (TPI), a novel thymidine phosphorylase inhibitor that improves the bioavailability of FTD."( TAS-102, a novel antitumor agent: a review of the mechanism of action.
Lenz, HJ; Loupakis, F; Stintzing, S, 2015
)
0.42
" TPI is an inhibitor of TFD degradation enzyme thymidine phosphorylase and thus increases the bioavailability of TFD."( TAS-102 an Emerging Oral Fluoropyrimidine.
Chen, J; Han, M; Saif, MW, 2016
)
0.43
" Maximum concentrations of both drugs decreased by approximately 40%, indicating that food influenced the absorption and bioavailability of trifluridine and tipiracil hydrochloride, respectively."( Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016
)
0.43
" The rapid degradation of TFT brought initial clinical development to a halt, but TFT reentered clinical trials when addition of a TPI was found to improve the bioavailability of TFT."( TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies.
Opdam, FL; van der Velden, DL; Voest, EE, 2016
)
0.43
" It is a combination of two active pharmaceutical compounds, trifluridine, an antineoplastic thymidine-based nucleoside analog, and tipiracil, which enhances the bioavailability of trifluridine in vivo."( Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.
Matsuoka, K; Nakagawa, F; Suzuki, N; Takechi, T, 2016
)
0.43
" A phase 1 study evaluated relative bioavailability of TAS-102 tablets compared with an oral solution containing equivalent amounts of FTD and TPI."( A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil.
Becerra, CR; Mizuguchi, H; Patel, M; Von Hoff, D; Yoshida, K, 2017
)
0.46
" Tipiracil blocks the degradation of trifluridine by thymidine phosphorylase, which improves the bioavailability of trifluridine and allows for oral administration."( The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan, BM; Hochster, HS; Lenz, HJ, 2019
)
0.51
"Trifluridine/tipiracil (TT) is an orally administered combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil hydrochloride, which increases the bioavailability of cytotoxic trifluridine."( First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.
Amellal, NC; André, T; Falcone, A; Fougeray, R; Gandossi, E; Kanehisa, A; Saunders, M, 2020
)
0.56
"Trifluridine/tipiracil (FTD/TPI) is an orally active formulation of trifluridine, a thymidine-based nucleoside analog, and tipiracil hydrochloride, a thymidine phosphorylase inhibitor that increases the bioavailability of trifluridine."( Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.
Amellal, N; Ciardiello, F; Fakih, M; Fougeray, R; Leger, C; Prager, GW; Tabernero, J; Taieb, J; van Cutsem, E, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves for its formation in [3H]thymidine-labeled DNA were constructed by exposing the DNA to increasing amounts of gamma-radiation and measuring the HMUra content."( Quantitative determination of the 5-(hydroxymethyl)uracil moiety in the DNA of gamma-irradiated cells.
Cadet, J; Cummings, A; Frenkel, K; Solomon, J; Steinberg, JJ; Teebor, GW, 1985
)
0.27
" Dose-response curves under aerobic and hypoxic conditions showed a much depressed base damage formation under hypoxia, which was created by blowing a stream of nitrogen across the cell suspensions for 30 min on ice."( Effect of misonidazole on formation of thymine damage by gamma rays.
Remsen, JF, 1985
)
0.54
" mirabilis and was found to be consistent with gene dosage effects."( Round of replication mutant of a drug resistance factor.
Hashimoto, H; Mickel, S; Morris, CF; Rownd, R, 1974
)
0.25
" Our hypothesis was that a relatively short and high dosage of TAS-102 results in an additional mechanism of FTD incorporation into DNA other than thymidylate synthase (TS) inhibition."( A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura, T; Fukushima, M; Ohshimo, H; Suzuki, N; Yamaguchi, M, 2004
)
0.32
" These changes appear to be stepwise, implying an allele dosage effect."( The -514 C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis.
Isaacs, A; Njajou, OT; Sayed-Tabatabaei, FA; van Duijn, CM; Witteman, JC, 2004
)
0.32
" These data may have important therapeutic and prognostic implication for P-gp-related drug dosage recommendation in Jewish populations."( Genotype and allele frequencies of C3435T polymorphism of the MDR1 gene in various Jewish populations of Israel.
Galski, H; Gazit, E; Korostishevsky, M; Nagler, A; Ostrovsky, O, 2004
)
0.32
"The following three features were found: (1) comparison between the two energies shows that the EPR dose-response curves are clearly distinguishable from each other: the curve for 407 eV saturated at a lower dose and spin number than that for 538 eV."( Low-energy Auger- and photo-electron effects on the degradation of thymine by ultrasoft X-irradiation.
Akamatsu, K; Fujii, K; Yokoya, A,
)
0.37
"The difference observed in the EPR dose-response relationship reflects the difference in the K-absorption cross-sections of carbon, nitrogen and oxygen in the thymine molecule which govern the photo-/Auger electron energy spectrum."( Low-energy Auger- and photo-electron effects on the degradation of thymine by ultrasoft X-irradiation.
Akamatsu, K; Fujii, K; Yokoya, A,
)
0.56
" Eighteen healthy volunteers received two 1-g doses of dicloxacillin, one on the 1st study day and the other on the 11th day of rifampin dosing (600 mg daily)."( Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics.
Benet, LZ; Huang, Y; Putnam, WS; Woo, JM, 2005
)
0.33
" The method has been successfully used to analyze commercial dosage form to assess the chromatographic performance of SFC system which was found to be 99."( Effect of system variables involved in packed column supercritical fluid chromatography of stavudine taken as model analyte using response surface methodology along with study of thermodynamic parameters.
Agrawal, H; Kaul, N; Mahadik, KR; Paradkar, AR, 2007
)
0.34
"This study was designed to determine the safety and optimal dosing of TAS-102, a novel oral combination of alphaalphaalpha-trifluorothymidine (FTD) and an inhibitor of thymidine phoshorylase, in patients with solid tumors."( Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.
Abbruzzese, JL; Fukushima, M; Hoff, PM; Kopetz, S; Kuwata, K; Mita, A; Overman, MJ; Thomas, MB; Varadhachary, G; Wolff, RA; Xiong, H, 2008
)
0.35
" Also a complete 12-hour pharmacokinetic profile was recorded for 15 transplant patients who had the polymorphism and for 15 controls who were randomly chosen since they received the same type and dosage of mycophenolate, same posttransplant time and similar renal function."( The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients.
Arroyo, M; Barrientos, A; Calvo, N; De la Orden, V; Maestro, ML; Ortega, D; Pérez-Flores, I; Sánchez-Fructuoso, AI; Veganzone, S; Viudarreta, M,
)
0.13
" The α(1D)-adrenoceptor antagonist, BMY-7378 (BMY) blocked noradrenaline-induced responses in the order SO > AC7 ≫ AC14; in contrast, the α(1A)-adrenoceptor antagonist RS-100329 (RS), produced a marginal shift to the right of the dose-response curve to noradrenaline, along with a strong decrease of the maximum pressor effect in the order SO > AC7 = AC14."( Effect of inter-renal aortic coarctation-induced hypertension on function and expression of vascular α(1A)- and α(1D)-adrenoceptors.
Gallardo-Ortiz, IA; Ibarra, M; López-Islas, I; López-Sánchez, P; Terrón, JA, 2012
)
0.38
" This compound is efficacious when dosed orally in an olanzapine-induced weight gain model in rats."( Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat.
Ahmed, S; Belanoff, J; Blasey, C; Buckley, G; Clark, RD; Daly, S; Hunt, HJ; Hynd, G; Lockey, P; O'Connor, E; Ray, NC; Roe, R; Sajad, M; Sutton, J, 2012
)
0.38
" Moreover, we recommend that, for patients with repeated treatment postponement due to neutropenia, the dosage should be fixed based on therapeutic efficacy and prognosis."( Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016
)
0.43
" It can be postulated that the dosage of TAS-102 potentially may need to be increased to achieve better outcomes in patients not experiencing any neutropenia."( Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Cecchini, M; Grothey, A; Hochster, HS; Kasi, PM; Kotani, D; Ohtsu, A; Ramanathan, RK; Shitara, K; Yoshino, T, 2016
)
0.43
" This Phase I, open-label, nonrandomized study investigated the safety, tolerability and pharmacokinetics of FTD/TPI in patients with advanced solid tumours (except breast cancer) and varying degrees of hepatic impairment, to provide dosing recommendations."( Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
Bebeau, P; Becerra, C; Rosen, L; Rudek, MA; Saif, MW; Shepard, DR; Sun, W; Winkler, R; Yamashita, F, 2019
)
0.51
"Regorafenib at different dosing strategies and TAS-102 are treatment options for refractory metastatic colorectal cancer (mCRC)."( A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Ahn, DH; Bekaii-Saab, T; Benkhadra, R; Firwana, B; Hubbard, JM; Mody, K; Murad, MH; Sonbol, MB; Walden, DJ; Wang, Z, 2019
)
0.51
"8%) had dosing modifications because of adverse events vs 101 (53."( Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.
Alsina, M; Arkenau, HT; Beretta, GD; Catenacci, D; Doi, T; Fujitani, K; George, B; Ghidini, M; Ilson, DH; Makris, L; Mansoor, W; McGuigan, S; Prokharau, A; Shitara, K; Tabernero, J; Thuss-Patience, P; Van Cutsem, E; Zhavrid, E, 2020
)
0.56
" The patient received several courses of chemotherapy with adjustments of the dose and dosing intervals to prevent neutropenia."( [Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
Amagasa, H; Ami, K; Ando, M; Fukuda, A; Gan, S; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Maeda, F; Motoyama, K; Okano, Y; Tokitou, F; Yamada, A, 2021
)
0.62
"Combination cancer chemotherapy is one of the most useful treatment methods to achieve a synergistic effect and reduce the toxicity of dosing with a single drug."( Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects.
Chang, CC; Hou, MH; Li, LY; Lin, SH; Neidle, S; Satange, R, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (3 Items)

ItemProcessFrequency
Groceriescore-ingredient1
Saucescore-ingredient1
Condimentscore-ingredient1

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyrimidine nucleobaseA nucleobase whose skeleton is derived from pyrimidine.
pyrimidoneA pyrimidine carrying one or more oxo substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (32)

PathwayProteinsCompounds
Metabolism14961108
Nucleotide metabolism89125
Nucleotide catabolism3671
Pyrimidine catabolism1025
DNA Repair25547
Base Excision Repair3523
Base-Excision Repair, AP Site Formation1716
Depyrimidination159
Cleavage of the damaged pyrimidine109
Pyrimidine Metabolism2353
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
Salvage Pathways of Pyrimidine Deoxyribonucleotides514
Pyrimidine Deoxyribonucleosides Degradation410
thymine degradation010
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides and Nucleosides metabolism )4549
Thymidine + Orthophosphate = 2-Deoxy-D-ribose 1-phosphate + Thymine ( Pyrimidine Nucleotides and Nucleosides metabolism )14
NADP+ + 5,6-Dihydro-thymine = NADPH + Thymine ( Pyrimidine Nucleotides and Nucleosides metabolism )14
Biomarkers for pyrimidine metabolism disorders1432
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Smith-Magenis and Potocki-Lupski syndrome copy number variation1399
pyrimidine deoxyribonucleosides degradation714
superpathway of pyrimidine deoxyribonucleosides degradation738
thymine degradation613
salvage pathways of pyrimidine deoxyribonucleotides432
superpathway of ribose and deoxyribose phosphate degradation024
(deoxy)ribose phosphate degradation018
purine and pyrimidine metabolism032
salvage pathways of purine and pyrimidine nucleotides030
Biochemical pathways: part I0466
Pyrimidine metabolism038
Pyrimidine metabolism and related diseases1844
DNA replication and repair5315
DNA repair4610
Base Excision Repair, AP site formation by depyrimidination32

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency68.58960.001530.607315,848.9004AID1224841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID155106The anti-HIV-1 activity was assayed in activated human peripheral blood mononuclear (PBM) cells, relative to RVT; not determined2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID1149713Antitumor activity against rat Walker 256 cells allografted in Sprague-Dawley rat at 2.5 mg/kg/day, ip relative to control1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antitumor agents. 25. Synthesis and antitumor activity of uracil and thymine alpha-methylene-gamma-lactones and related derivatives.
AID477229Cytotoxicity against human KB cells at 30 uM2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Agelastatin E, agelastatin F, and benzosceptrin C from the marine sponge Agelas dendromorpha.
AID501987Antiviral activity against Influenza B virus Florida/4/2006 infected in MDCK cells2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Novel nucleosides as potent influenza viral inhibitors.
AID211081Inhibitory activity against mouse liver thymidine phosphorylase at 0.15 mM thymidine substrate2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening.
AID501986Antiviral activity against Influenza A virus H5N1 Vietnam/1203/2004H infected in MDCK cells2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Novel nucleosides as potent influenza viral inhibitors.
AID501988Cytotoxicity against MDCK cells2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Novel nucleosides as potent influenza viral inhibitors.
AID47311Cytotoxicity was determined in CEM cells, relative to RVT2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID217732Cytotoxicity was determined in Vero cells, relative to RVT2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID1149714Antitumor activity against mouse P388 cells allografted in DBA/2 mouse at 25 mg/kg/day, ip administered for 2 weeks relative to control1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antitumor agents. 25. Synthesis and antitumor activity of uracil and thymine alpha-methylene-gamma-lactones and related derivatives.
AID1149715Antitumor activity against mouse B16 cells allografted in C57Bl/6 mouse at 25 mg/kg/day, ip administered for 2 weeks relative to control1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antitumor agents. 25. Synthesis and antitumor activity of uracil and thymine alpha-methylene-gamma-lactones and related derivatives.
AID155120The anti-HIV-1 activity was assayed in activated human peripheral blood mononuclear (PBM) cells, relative to RVT; not determined2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID155299Cytotoxicity was determined in PBM cells, relative to RVT2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,849)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903058 (44.65)18.7374
1990's755 (11.02)18.2507
2000's1430 (20.88)29.6817
2010's1234 (18.02)24.3611
2020's372 (5.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.32 (24.57)
Research Supply Index8.88 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index138.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (75.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials79 (1.12%)5.53%
Reviews212 (3.00%)6.00%
Case Studies134 (1.90%)4.05%
Observational10 (0.14%)0.25%
Other6,636 (93.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]